MXC.AX - MGC Pharmaceuticals Limited

ASX - ASX Delayed price. Currency in AUD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2022
30/06/2021
30/06/2020
30/06/2019
Total revenue
4,732
4,647
2,963
2,035
656.237
Cost of revenue
2,922
3,014
1,652
1,905
356.642
Gross profit
1,810
1,633
1,310
2,035
299.595
Operating expenses
Research development
1,608
-
-
-
2,866
Selling general and administrative
10,312
9,233
6,313
6,609
3,187
Total operating expenses
16,071
15,083
13,380
12,069
9,339
Operating income or loss
-14,261
-13,450
-12,070
-10,034
-9,039
Interest expense
210.142
190.048
369.135
135.582
8
Total other income/expenses net
-6,297
-3,499
-1,100
-8,657
6,969
Income before tax
-20,768
-17,139
-13,532
-18,814
-1,876
Income tax expense
0
0
-27.278
0
27.315
Income from continuing operations
-20,768
-17,139
-13,504
-18,814
-1,904
Net income
-20,347
-16,766
-13,965
-19,363
-2,309
Net income available to common shareholders
-20,347
-16,766
-13,965
-19,363
-2,309
Basic EPS
-
-0.01
-0.01
-0.01
-0.00
Diluted EPS
-
-0.01
-0.01
-0.01
-0.00
Basic average shares
-
2,566,211
1,906,115
1,382,195
1,209,142
Diluted average shares
-
2,566,211
1,906,115
1,382,195
1,209,142
EBITDA
-
-16,444
-12,671
-18,679
-1,609